Investor
REGENERON PHARMACEUTICALS, INC.
CIK 0000872589 · filed 2026-05-08 · SEC filing
13F book
$47.9M
Positions
2
Largest name
99.1%
Intellia Therapeutics, Inc. · NTLA
Est. mark
$14.1M
Price effect on 2 names still held. Flow −$0.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Intellia Therapeutics, Inc. | NTLA | 3.7M | $47.5M | 99.1% | $14.2M | Held |
| Adicet Bio, Inc. | ACET | 60.5K | $412.1K | 0.9% | −$97.4K | Held |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.